case_images: PMC11211372_01
case_images: PMC11211372_02
case_images: (A) 2013 lung CT, red arrow indicating more progressive lesions in the right lung (after chemotherapy). (B). 2013 lung CT, CIK cell therapy combined with chemotherapy after 3 months, the red arrow indicates a reduction in lesions in the right lung. (C). 2016 lung CT. CIK cell therapy combined with chemotherapy. Red arrow indicates lesions in the right lung. (D). 2023 lung CT. Red arrows indicate stable lesions in the right lung.
case_images: fonc-14-1389725-g001.jpg
case_images: PMC11211372_02_fonc-14-1389725-g001.jpg
case_images: f1
case_images: With the progression of the disease, the patient's primary lesion showed signs of growth ( Figure 1A ), and because of the side effects of toxic drugs, the patient showed symptoms such as nausea and vomiting. Four months after CIK immune cell therapy combined with chemotherapy, we reviewed lung CT, and the imaging results showed that the primary lung lesions were significantly reduced ( Figure 1B ). At the end of the treatment cycle of CIK cell therapy combined with chemotherapy, there was no significant progression of the lung lesions ( Figure 1C ). In the latest lung impact data ( Figure 1D ), we could observe that the patient's lung tumors were stable.
case_images: Treatment process from 2011 to 2023. Immune cell therapy, chemotherapy, and radiotherapy are all represented in the upper part of the figure, with different colors and text descriptions representing different treatment modalities displayed in the upper part of the panel. The changes of WBC count and tumor markers CEA and NSE are shown in the line charts. The blue square represents CEA, the red dot represents WBC count, the triangle line chart represents NSE, and the CD3+CD4+ lymphocyte count and CD4/CD8 ratio changes are shown above the NSE line. CEA, Carcinoembryonic antigen; NSE, Neuron-specific enolase; WBC: White blood cell count.
case_images: fonc-14-1389725-g002.jpg
case_images: PMC11211372_02_fonc-14-1389725-g002.jpg
case_images: f2
case_images: At the same time, we observed the patient's WBC and HB indices, both of which were within the acceptable range, and almost no adverse events occurred in this treatment mode ( Figure 2 ).